Dr Reddys Laboratories Ltd Technical Momentum Shifts Amid Bearish Signals

Technical Trend Overview and Price Movement

The stock currently trades at ₹1,160.65, down 0.79% from the previous close of ₹1,169.90. Intraday volatility saw a high of ₹1,179.65 and a low of ₹1,155.05, with the 52-week range spanning ₹1,080.05 to ₹1,414.40. The recent technical trend has shifted from a neutral sideways pattern to a mildly bearish one, signalling a cautious outlook among traders and investors.

On a comparative basis, Dr Reddys Laboratories has underperformed the Sensex over the past month, with a stock return of -15.56% against the Sensex’s 0.86%. Year-to-date, the stock is down 8.69%, slightly worse than the Sensex’s decline of 7.97%. Over longer horizons, the stock’s performance remains subdued relative to the benchmark, with a 5-year return of 21.63% versus Sensex’s 44.25%, and a 10-year return of 95.80% compared to Sensex’s 182.99%.

MACD and Momentum Indicators Signal Bearishness

The Moving Average Convergence Divergence (MACD) indicator presents a bearish outlook on the weekly chart, while the monthly MACD is mildly bearish. This suggests that short-term momentum is weakening, with the possibility of further downside pressure. The bearish weekly MACD aligns with the recent price decline and the shift in trend, indicating that sellers have gained some control in the near term.

Meanwhile, the Relative Strength Index (RSI) remains neutral on both weekly and monthly timeframes, signalling no clear overbought or oversold conditions. This lack of RSI signal implies that the stock is not yet in an extreme momentum phase, but the absence of bullish RSI support adds to the cautious technical stance.

Bollinger Bands and Moving Averages Reflect Mixed Signals

Bollinger Bands on both weekly and monthly charts are mildly bearish, indicating that price volatility is skewed towards the downside. The bands suggest that the stock is trading closer to the lower band, which often precedes a period of consolidation or further decline if selling pressure persists.

Contrastingly, daily moving averages show a mildly bullish trend, hinting at some short-term support. This divergence between daily moving averages and longer-term indicators like weekly MACD and Bollinger Bands highlights a technical tug-of-war, where short-term buyers are attempting to stabilise prices amid broader bearish momentum.

Additional Technical Indicators: KST, Dow Theory, and OBV

The Know Sure Thing (KST) indicator presents a mixed picture: bearish on the weekly timeframe but bullish on the monthly. This divergence suggests that while short-term momentum is weakening, the longer-term trend may still hold some upside potential. Investors should monitor this indicator closely for confirmation of trend direction in the coming weeks.

Dow Theory assessments align with the mildly bearish weekly trend, while the monthly Dow Theory shows no clear trend. This reinforces the notion of short-term caution without a definitive long-term directional bias.

On-Balance Volume (OBV) is bearish on the weekly chart, indicating that volume trends support the recent price decline. However, the monthly OBV shows no clear trend, suggesting that longer-term accumulation or distribution is not decisively skewed.

Market Capitalisation and Mojo Score Insights

Dr Reddys Laboratories is classified as a mid-cap stock with a Mojo Score of 36.0, which corresponds to a Sell rating. This represents a downgrade from the previous Hold grade as of 13 July 2026, reflecting deteriorating technical and fundamental conditions. The downgrade signals increased caution for investors, especially given the stock’s recent underperformance relative to the broader market and sector peers.

Price Returns Compared to Sensex

Examining returns over various periods highlights the stock’s relative weakness. While the stock outperformed the Sensex marginally over the past week with a 2.20% gain versus 2.17%, it has lagged significantly over the past month and year. The 1-month return of -15.56% contrasts sharply with the Sensex’s positive 0.86%, and the 1-year return of -5.28% trails the Sensex’s -3.20%. Longer-term returns over three and five years also show underperformance, underscoring challenges in sustaining growth momentum.

Implications for Investors

The technical signals suggest that Dr Reddys Laboratories is currently navigating a phase of mild bearishness, with short-term momentum indicators pointing to potential downside risks. The mixed signals from daily moving averages and monthly KST indicate that while some support exists, investors should remain cautious and watch for confirmation of trend direction.

Given the downgrade to a Sell rating and the stock’s underperformance relative to the Sensex, investors may consider reassessing their exposure to Dr Reddys Laboratories, particularly in the context of sector and peer comparisons.

Conclusion: Navigating a Cautious Technical Landscape

Dr Reddys Laboratories Ltd is currently exhibiting a technical profile marked by mildly bearish momentum and mixed indicator signals. The downgrade in Mojo Grade to Sell reflects the challenges faced by the stock amid broader market volatility and sector-specific pressures. While some short-term bullish signals persist, the overall technical landscape advises prudence.

Investors should closely monitor key technical indicators such as MACD, Bollinger Bands, and KST for signs of trend reversal or further deterioration. Additionally, comparative performance against the Sensex and sector peers should inform portfolio decisions, especially given the stock’s recent underperformance and mid-cap status.

In this environment, a balanced approach that weighs both technical signals and fundamental factors will be essential for navigating the evolving market dynamics surrounding Dr Reddys Laboratories.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →